You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 5, 2024

~ Buy the ILLUCCIX (gallium ga-68 gozetotide) Drug Profile, 2024 PDF Report in the Report Store ~

CLINICAL TRIALS PROFILE FOR ILLUCCIX


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for ILLUCCIX

Trial ID Title Status Sponsor Phase Start Date Summary
NCT05558956 ↗ Total Body PET-CT Imaging of Prostate Cancer Using Illuccix Not yet recruiting Telix International Pty Ltd Early Phase 1 2022-10-01 Illuccix will be used per the prescribing instructions for PET-CT imaging on the United Imaging scanner uEXPLORER to establish a standard scanning protocol.
NCT05558956 ↗ Total Body PET-CT Imaging of Prostate Cancer Using Illuccix Not yet recruiting BAMF Health Early Phase 1 2022-10-01 Illuccix will be used per the prescribing instructions for PET-CT imaging on the United Imaging scanner uEXPLORER to establish a standard scanning protocol.
NCT05847348 ↗ 68Ga-PSMA-11 Efficacy in Detecting BCR Prostate Cancer in Chinese Patients Not yet recruiting Grand Pharmaceutical (China) Co., Ltd. Phase 3 2023-06-30 This is a prospective, open-label, single-arm, multicenter bridging study in Chinese patients with prostate cancer. This multicenter study is planned to be conducted in patients with biochemical recurrence (BCR) of elevated PSA after radical prostatectomy or radical radiotherapy. This study investigates how well 68Ga-PSMA-11 PET/CT works in detecting BCR prostate cancer in Chinese patient. 68Ga-PSMA-11, developed by Telix, is a new molecular entity tracer with the trade name Illuccix®, which is approved by FDA for the examination of: 1) patients with suspected metastatic PC who are scheduled for initial treatment; 2) patients with biochemical recurrence of elevated PSA levels after initial radical radiotherapy.
NCT05847348 ↗ 68Ga-PSMA-11 Efficacy in Detecting BCR Prostate Cancer in Chinese Patients Not yet recruiting Telix International Pty Ltd Phase 3 2023-06-30 This is a prospective, open-label, single-arm, multicenter bridging study in Chinese patients with prostate cancer. This multicenter study is planned to be conducted in patients with biochemical recurrence (BCR) of elevated PSA after radical prostatectomy or radical radiotherapy. This study investigates how well 68Ga-PSMA-11 PET/CT works in detecting BCR prostate cancer in Chinese patient. 68Ga-PSMA-11, developed by Telix, is a new molecular entity tracer with the trade name Illuccix®, which is approved by FDA for the examination of: 1) patients with suspected metastatic PC who are scheduled for initial treatment; 2) patients with biochemical recurrence of elevated PSA levels after initial radical radiotherapy.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for ILLUCCIX

Condition Name

Condition Name for ILLUCCIX
Intervention Trials
BCR Prostate Carcinoma 1
Biochemical Recurrence of Malignant Neoplasm of Prostate 1
Metastatic Castration-resistant Prostate Cancer 1
Prostate Cancer 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for ILLUCCIX
Intervention Trials
Prostatic Neoplasms 2
Recurrence 1
Neoplasms 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for ILLUCCIX

Trials by Country

Trials by Country for ILLUCCIX
Location Trials
China 1
United States 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for ILLUCCIX
Location Trials
Michigan 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for ILLUCCIX

Clinical Trial Phase

Clinical Trial Phase for ILLUCCIX
Clinical Trial Phase Trials
Phase 3 1
Early Phase 1 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for ILLUCCIX
Clinical Trial Phase Trials
Not yet recruiting 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for ILLUCCIX

Sponsor Name

Sponsor Name for ILLUCCIX
Sponsor Trials
Telix International Pty Ltd 2
BAMF Health 1
Grand Pharmaceutical (China) Co., Ltd. 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for ILLUCCIX
Sponsor Trials
Other 2
Industry 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.